{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:04:25Z","timestamp":1792839865464,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40259-025-00729-x","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T18:21:07Z","timestamp":1749752467000},"page":"573-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3391-5867","authenticated-orcid":false,"given":"Angela H.","family":"Holian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5806-6203","authenticated-orcid":false,"given":"Brian G.","family":"Weinshenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"729_CR1","doi-asserted-by":"crossref","unstructured":"Hor JY, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020;11.","DOI":"10.3389\/fneur.2020.00501"},{"issue":"9","key":"729_CR2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805\u201315.","journal-title":"Lancet Neurol"},{"issue":"7","key":"729_CR3","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/archneur.63.7.964","volume":"63","author":"SJ Pittock","year":"2006","unstructured":"Pittock SJ, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006;63(7):964\u20138.","journal-title":"Arch Neurol"},{"issue":"9","key":"729_CR4","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1001\/jamaneurol.2013.3124","volume":"70","author":"M Matiello","year":"2013","unstructured":"Matiello M, et al. Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica. JAMA Neurol. 2013;70(9):1118\u201325.","journal-title":"JAMA Neurol"},{"issue":"8","key":"729_CR5","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/01.wnl.0000343001.36493.ae","volume":"72","author":"SM Maga\u00f1a","year":"2009","unstructured":"Maga\u00f1a SM, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology. 2009;72(8):712\u20137.","journal-title":"Neurology"},{"issue":"6","key":"729_CR6","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1093\/brain\/awz106","volume":"142","author":"E Cotzomi","year":"2019","unstructured":"Cotzomi E, et al. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain. 2019;142(6):1598\u2013615.","journal-title":"Brain"},{"issue":"5","key":"729_CR7","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","volume":"266","author":"R Wynford-Thomas","year":"2019","unstructured":"Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody disease. J Neurol. 2019;266(5):1280\u20136.","journal-title":"J Neurol"},{"issue":"5","key":"729_CR8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, et al. The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology. 1999;53(5):1107\u201314.","journal-title":"Neurology"},{"issue":"10","key":"729_CR9","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485\u20139.","journal-title":"Neurology"},{"issue":"2","key":"729_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177\u201389.","journal-title":"Neurology"},{"issue":"5","key":"729_CR11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ana.22121","volume":"68","author":"M Apiwattanakul","year":"2010","unstructured":"Apiwattanakul M, et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol. 2010;68(5):757\u201361.","journal-title":"Ann Neurol"},{"issue":"9","key":"729_CR12","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1212\/01.wnl.0000183151.19351.82","volume":"65","author":"T Misu","year":"2005","unstructured":"Misu T, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005;65(9):1479\u201382.","journal-title":"Neurology"},{"issue":"6","key":"729_CR13","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","volume":"46","author":"BG Weinshenker","year":"1999","unstructured":"Weinshenker BG, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46(6):878\u201386.","journal-title":"Ann Neurol"},{"issue":"5","key":"729_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s11095-022-03236-8","volume":"39","author":"SK Singh","year":"2022","unstructured":"Singh SK, et al. A charge variant of bevacizumab offers enhanced FcRn-dependent pharmacokinetic half-life and efficacy. Pharm Res. 2022;39(5):851\u201365.","journal-title":"Pharm Res"},{"issue":"1","key":"729_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/ene.15561","volume":"30","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks. Eur J Neurol. 2023;30(1):195\u2013203.","journal-title":"Eur J Neurol"},{"issue":"4","key":"729_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/cen3.12239","volume":"6","author":"MA Mealy","year":"2015","unstructured":"Mealy MA, et al. Bevacizumab is safe in acute relapses of neuromyelitis optica. Clin Exp Neuroimmunol. 2015;6(4):413\u20138.","journal-title":"Clin Exp Neuroimmunol"},{"key":"729_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107827","volume":"162","author":"T Duan","year":"2020","unstructured":"Duan T, et al. Affinity-matured \u201caquaporumab\u201d anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. Neuropharmacology. 2020;162: 107827.","journal-title":"Neuropharmacology"},{"issue":"3","key":"729_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/ana.22657","volume":"71","author":"L Tradtrantip","year":"2012","unstructured":"Tradtrantip L, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol. 2012;71(3):314\u201322.","journal-title":"Ann Neurol"},{"issue":"4","key":"729_CR19","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","volume":"51","author":"RN Mandler","year":"1998","unstructured":"Mandler RN, Ahmed W, Dencoff JE. Devic\u2019s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51(4):1219\u201320.","journal-title":"Neurology"},{"issue":"9","key":"729_CR20","doi-asserted-by":"publisher","first-page":"716","DOI":"10.7326\/0003-4819-129-9-199811010-00007","volume":"129","author":"AJ Black","year":"1998","unstructured":"Black AJ, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998;129(9):716\u20138.","journal-title":"Ann Intern Med"},{"issue":"10","key":"729_CR21","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1177\/1352458516678474","volume":"23","author":"A Montcuquet","year":"2017","unstructured":"Montcuquet A, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017;23(10):1377\u201384.","journal-title":"Mult Scler"},{"issue":"9","key":"729_CR22","first-page":"1128","volume":"66","author":"MMM Anu Jacob","year":"2009","unstructured":"Anu Jacob MMM, Weinshenker B. Treatment of neuromyelitis optica with mycophenolate mofetil. Arch Neurol. 2009;66(9):1128\u201333.","journal-title":"Arch Neurol"},{"issue":"5","key":"729_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40262-013-0039-8","volume":"52","author":"AN Abd Rahman","year":"2013","unstructured":"Abd Rahman AN, Tett SE, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. Clin Pharmacokinet. 2013;52(5):303\u201331.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"729_CR24","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BA Cree","year":"2005","unstructured":"Cree BA, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270\u20132.","journal-title":"Neurology"},{"issue":"24","key":"729_CR25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2121804119","volume":"119","author":"V Damato","year":"2022","unstructured":"Damato V, et al. Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders. Proc Natl Acad Sci USA. 2022;119(24): e2121804119.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"729_CR26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298\u2013306.","journal-title":"Lancet Neurol"},{"issue":"11","key":"729_CR27","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob A, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443\u20138.","journal-title":"Arch Neurol"},{"issue":"6","key":"729_CR28","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","volume":"100","author":"LE van der Kolk","year":"2002","unstructured":"van der Kolk LE, et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100(6):2257\u20139.","journal-title":"Blood"},{"key":"729_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-3-031-04402-1_7","volume":"184","author":"CL Bennett","year":"2022","unstructured":"Bennett CL, Witherspoon B, Carson KR. Rituximab-associated progressive multifocal leukoencephalopathy: a twenty-year update. Cancer Treat Res. 2022;184:103\u201311.","journal-title":"Cancer Treat Res"},{"issue":"20","key":"729_CR30","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834\u201340.","journal-title":"Blood"},{"key":"729_CR31","doi-asserted-by":"crossref","unstructured":"van Vollenhoven RF, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496\u2013502.","DOI":"10.1136\/annrheumdis-2012-201956"},{"issue":"2","key":"729_CR32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.2174\/18756190MTA2cMjAm1","volume":"19","author":"I Lotan","year":"2021","unstructured":"Lotan I, McGowan R, Levy M. Anti-IL-6 therapies for neuromyelitis optica spectrum disorders: a systematic review of safety and efficacy. Curr Neuropharmacol. 2021;19(2):220\u201332.","journal-title":"Curr Neuropharmacol"},{"issue":"15","key":"729_CR33","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","volume":"82","author":"M Araki","year":"2014","unstructured":"Araki M, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82(15):1302\u20136.","journal-title":"Neurology"},{"issue":"5","key":"729_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","volume":"19","author":"C Zhang","year":"2020","unstructured":"Zhang C, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391\u2013401.","journal-title":"Lancet Neurol"},{"issue":"3","key":"729_CR35","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s13311-022-01206-x","volume":"19","author":"V Redenbaugh","year":"2022","unstructured":"Redenbaugh V, Flanagan EP. Monoclonal antibody therapies beyond complement for NMOSD and MOGAD. Neurotherapeutics. 2022;19(3):808\u201322.","journal-title":"Neurotherapeutics"},{"issue":"6","key":"729_CR36","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMoa031688","volume":"350","author":"P Hillmen","year":"2004","unstructured":"Hillmen P, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350(6):552\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"729_CR37","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233\u201343.","journal-title":"N Engl J Med"},{"key":"729_CR38","unstructured":"Alexion Pharmaceuticals, I. Soliris (eculizumab) [Package insert]. Boston, MA. 2021."},{"issue":"6","key":"729_CR39","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12(6):554\u201362.","journal-title":"Lancet Neurol"},{"issue":"6","key":"729_CR40","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock SJ, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023;93(6):1053\u201368.","journal-title":"Ann Neurol"},{"issue":"10206","key":"729_CR41","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet"},{"issue":"12","key":"729_CR42","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","volume":"80","author":"JE Frampton","year":"2020","unstructured":"Frampton JE. Inebilizumab: first approval. Drugs. 2020;80(12):1259\u201364.","journal-title":"Drugs"},{"issue":"1","key":"729_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jaip.2016.06.022","volume":"5","author":"AS Levin","year":"2017","unstructured":"Levin AS, et al. Reactions to rituximab in an outpatient infusion center: a 5-year review. J Allergy Clin Immunol Pract. 2017;5(1):107-113.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"729_CR44","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676\u201388.","journal-title":"N Engl J Med"},{"issue":"5","key":"729_CR45","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11910-008-0064-4","volume":"8","author":"D Bourdette","year":"2008","unstructured":"Bourdette D, Yadav V. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. Curr Neurol Neurosci Rep. 2008;8(5):417\u20138.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"729_CR46","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1080\/14737175.2020.1757434","volume":"20","author":"M Rosso","year":"2020","unstructured":"Rosso M, Saxena S, Chitnis T. Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options. Expert Rev Neurother. 2020;20(5):509\u201316.","journal-title":"Expert Rev Neurother"},{"issue":"22","key":"729_CR47","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114\u201324.","journal-title":"N Engl J Med"},{"issue":"5","key":"729_CR48","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402\u201312.","journal-title":"Lancet Neurol"},{"key":"729_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104025","volume":"66","author":"T Yamamura","year":"2022","unstructured":"Yamamura T, et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022;66: 104025.","journal-title":"Mult Scler Relat Disord"},{"key":"729_CR50","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz054","volume":"142","author":"J Palace","year":"2019","unstructured":"Palace J, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain. 2019;142:1310\u201323.","journal-title":"Brain"},{"issue":"1","key":"729_CR51","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)-revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management. J Neurol. 2024;271(1):141\u201376.","journal-title":"J Neurol"},{"issue":"14","key":"729_CR52","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","volume":"81","author":"Y Jiao","year":"2013","unstructured":"Jiao Y, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81(14):1197\u2013204.","journal-title":"Neurology"},{"issue":"3","key":"729_CR53","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000225","volume":"3","author":"M Sep\u00falveda","year":"2016","unstructured":"Sep\u00falveda M, et al. Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm. 2016;3(3): e225.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"729_CR54","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016;73(11):1342\u20138.","journal-title":"JAMA Neurol"},{"key":"729_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102843","volume":"50","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta-analysis. Mult Scler Relat Disord. 2021;50: 102843.","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"729_CR56","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/ana.26049","volume":"89","author":"DM Wingerchuk","year":"2021","unstructured":"Wingerchuk DM, et al. Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Ann Neurol. 2021;89(6):1088\u201398.","journal-title":"Ann Neurol"},{"key":"729_CR57","doi-asserted-by":"crossref","unstructured":"Kleiter I, et al. Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2023;10(1).","DOI":"10.1212\/NXI.0000000000200071"},{"issue":"6","key":"729_CR58","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/13524585211047223","volume":"28","author":"M Rensel","year":"2022","unstructured":"Rensel M, et al. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for \u22654 years in the N-MOmentum trial. Mult Scler. 2022;28(6):925\u201332.","journal-title":"Mult Scler"},{"issue":"7","key":"729_CR59","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614\u201325.","journal-title":"N Engl J Med"},{"key":"729_CR60","unstructured":"Ltd FH-LR. A study to evaluate the efficacy and safety of satralizumab in participants with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). 03\/17\/2025 April 24, 2025. 2022. https:\/\/clinicaltrials.gov\/study\/NCT05271409."},{"key":"729_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104938","volume":"79","author":"K Fujihara","year":"2023","unstructured":"Fujihara K, et al. Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: subgroup analyses of the N-MOmentum study. Mult Scler Relat Disord. 2023;79: 104938.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"729_CR62","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40120-021-00295-8","volume":"11","author":"DM Wingerchuk","year":"2022","unstructured":"Wingerchuk DM, et al. Network meta-analysis of Food and Drug Administration-approved treatment options for adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder. Neurol Ther. 2022;11(1):123\u201335.","journal-title":"Neurol Ther"},{"issue":"3","key":"729_CR63","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s40120-022-00376-2","volume":"11","author":"BAC Cree","year":"2022","unstructured":"Cree BAC, et al. Letter to the editor regarding \u201cNetwork Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.\u201d Neurol Ther. 2022;11(3):1439\u201343.","journal-title":"Neurol Ther"},{"issue":"3","key":"729_CR64","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1128\/CMR.4.3.359","volume":"4","author":"JE Figueroa","year":"1991","unstructured":"Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. 1991;4(3):359\u201395.","journal-title":"Clin Microbiol Rev"},{"issue":"23","key":"729_CR65","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381.","journal-title":"N Engl J Med"},{"issue":"9","key":"729_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","volume":"69","author":"SA Mbaeyi","year":"2020","unstructured":"Mbaeyi SA, et al. Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1\u201341.","journal-title":"MMWR Recomm Rep"},{"issue":"19","key":"729_CR67","doi-asserted-by":"publisher","first-page":"509","DOI":"10.15585\/mmwr.mm6619a6","volume":"66","author":"ME Patton","year":"2017","unstructured":"Patton ME, et al. Updated recommendations for use of MenB-FHbp Serogroup B meningococcal vaccine\u2014advisory committee on immunization practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(19):509\u201313.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"729_CR68","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1017\/S1092852919001627","volume":"26","author":"J Avasarala","year":"2021","unstructured":"Avasarala J, Sokola BS, Mullins S. Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder. CNS Spectr. 2021;26(3):185\u20137.","journal-title":"CNS Spectr"},{"issue":"5","key":"729_CR69","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/BOR.0000000000000633","volume":"31","author":"P Conigliaro","year":"2019","unstructured":"Conigliaro P, et al. Complement, infection, and autoimmunity. Curr Opin Rheumatol. 2019;31(5):532\u201341.","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"729_CR70","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209888","volume":"103","author":"M Ringelstein","year":"2024","unstructured":"Ringelstein M, et al. Eculizumab use in neuromyelitis optica spectrum disorders: routine clinical care data from a European cohort. Neurology. 2024;103(9): e209888.","journal-title":"Neurology"},{"issue":"12","key":"729_CR71","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen H, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853\u201361.","journal-title":"Lancet Infect Dis"},{"issue":"41","key":"729_CR72","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","volume":"64","author":"JR MacNeil","year":"2015","unstructured":"MacNeil JR, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"729_CR73","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.rdc.2016.09.009","volume":"43","author":"ES Molloy","year":"2017","unstructured":"Molloy ES, Calabrese CM, Calabrese LH. The risk of progressive multifocal leukoencephalopathy in the biologic era: prevention and management. Rheum Dis Clin N Am. 2017;43(1):95\u2013109.","journal-title":"Rheum Dis Clin N Am"},{"key":"729_CR74","unstructured":"Genentech I. ENSPRYNG (satralizumab-mwge) injection, for subcutaneous use. Genentech, Inc: South San Francisco, CA. 2022."},{"key":"729_CR75","unstructured":"Genentech I. Tocilizumab [Actemra] package insert. South San Francisco, CA. 2024."},{"key":"729_CR76","unstructured":"Services CfMM. Medicare Part B drug average sales price (ASP) data. n.d."},{"issue":"1","key":"729_CR77","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/jnnp-2021-326386","volume":"93","author":"H Masuda","year":"2022","unstructured":"Masuda H, et al. Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry. 2022;93(1):32\u201340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"729_CR78","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","volume":"18","author":"I Nakashima","year":"2011","unstructured":"Nakashima I, et al. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci. 2011;18(7):997\u20138.","journal-title":"J Clin Neurosci"},{"issue":"6","key":"729_CR79","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood. 1997;90(6):2188\u201395.","journal-title":"Blood"},{"issue":"12","key":"729_CR80","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1002\/acn3.51911","volume":"10","author":"HJ Kim","year":"2023","unstructured":"Kim HJ, et al. Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism. Ann Clin Transl Neurol. 2023;10(12):2413\u201320.","journal-title":"Ann Clin Transl Neurol"},{"key":"729_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103352","volume":"57","author":"EP Flanagan","year":"2022","unstructured":"Flanagan EP, et al. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Mult Scler Relat Disord. 2022;57: 103352.","journal-title":"Mult Scler Relat Disord"},{"key":"729_CR82","doi-asserted-by":"crossref","unstructured":"Osborne B, et al. Case report: transition from anti-CD20 therapy to inebilizumab for 14 cases of neuromyelitis optica spectrum disorder. Front Neurol. 2024;15.","DOI":"10.3389\/fneur.2024.1352779"},{"issue":"5","key":"729_CR83","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ana.26067","volume":"89","author":"O Aktas","year":"2021","unstructured":"Aktas O, et al. Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker. Ann Neurol. 2021;89(5):895\u2013910.","journal-title":"Ann Neurol"},{"issue":"9","key":"729_CR84","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2022-330412","volume":"94","author":"O Aktas","year":"2023","unstructured":"Aktas O, et al. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry. 2023;94(9):757\u201368.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"17","key":"729_CR85","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1073\/pnas.1820039116","volume":"116","author":"I Zubizarreta","year":"2019","unstructured":"Zubizarreta I, et al. Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proc Natl Acad Sci USA. 2019;116(17):8463\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"729_CR86","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","volume":"22","author":"JR Corboy","year":"2023","unstructured":"Corboy JR, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol. 2023;22(7):568\u201377.","journal-title":"Lancet Neurol"},{"issue":"3","key":"729_CR87","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/13524585211038291","volume":"28","author":"SJ Pittock","year":"2022","unstructured":"Pittock SJ, et al. Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension. Mult Scler. 2022;28(3):480\u20136.","journal-title":"Mult Scler"},{"key":"729_CR88","unstructured":"Horizon Therapeutics USA, I., Uplizna (inebilizumab-cdon) [Package insert]. Deerfield, IL. 2022."},{"key":"729_CR89","unstructured":"Alexion Pharmaceuticals, I. Ultomiris (ravulizumab-cwvz) [Package insert]. Boston, MA. 2022."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00729-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00729-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00729-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T16:02:08Z","timestamp":1750694528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00729-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["729"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00729-x","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"11 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Angela Holian has no conflicts of interest that are directly relevant to the content of this article. Brian Weinshenker received payments for serving as chair of attack adjudication committees for clinical trials in neuromyelitis optica spectrum disorders conducted by Alexion, Medimmune, and VielaBio\/Horizon Therapeutics, and receives payments as chair of the attack adjudication committee for a clinical trial in MOGAD conducted by UCB Biosciences. He has consulted with Chugai, Genentech, Roche, Mitsubishi Tanabe, and CANbridge pharmaceuticals regarding clinical trial designs for neuromyelitis optica spectrum disorders. He has received speaking fees from Genentech, Horizon Therapeutics, Roche, and Mitsubishi Tanabe. He has a patent for NMO-IgG for diagnosis of neuromyelitis optica, with royalties paid by Hospice Civil de Lyon, MVZ PD Dr. Volkmann und Kollegen GbR, Oxford University and RSR Limited.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data analyzed and presented are published.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors wrote and revised the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}